about
Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myelomaActivation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cellsVariation in innate immunity genes and risk of multiple myelomaMultiple myeloma macrophages: pivotal players in the tumor microenvironment.Constitutive NF-kappaB activation confers interleukin 6 (IL6) independence and resistance to dexamethasone and Janus kinase inhibitor INCB018424 in murine plasmacytoma cells.Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalitiesEffects of all-trans retinoic acid (ATRA) on human myeloma cells.MicroRNAs: New Players in Multiple Myeloma.Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway.New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression.Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cellsCD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNγ cytokines and proliferation.Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer.Extracavitary primary effusion lymphoma presenting as a cutaneous tumor: a case report and literature review.Oncolytic virotherapy for multiple myeloma: past, present, and future.Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways.In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma.Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage.Cutaneous plasmablastic lymphoma in an HIV-positive male: an unrecognized cutaneous manifestation.Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.Osteoclast-like cell formation by circulating myeloma B lymphocytes: role of RANK-L.Anti-myeloma Effects of Icariin Are Mediated Through the Attenuation of JAK/STAT3-Dependent Signaling Cascade.
P2860
Q24670255-02ADA99C-05C8-48A8-8B0C-6DA3437E35F4Q28204011-BCF1BE4C-10D0-4F22-88BD-49D9BF84E0BBQ28542491-F6B95A93-7B23-4F0C-B939-3254382F2197Q34306330-06CE5DA1-4DFC-49EF-9D6A-A44BBCCBD058Q34329152-FA86CA71-CA17-440E-90B6-EEE5DE6196B9Q35150054-85F54D52-3F7E-4C25-9DC4-B67DD3BD03ACQ35534247-C41BA09D-993D-4888-9E62-E01F95117ED8Q35614620-1FDDF9E7-472C-414F-921F-77C7CA152703Q35711092-196E88CF-6A9F-42E9-9015-94B139792C87Q36092102-8B8B8995-59D9-4A57-8DC2-7A1E24DF67CAQ36693641-3F743E5A-703F-465E-A66D-91560C8E66B9Q37340398-EE3A3F86-D420-49A6-88F0-301F626407BDQ37481912-EBA4FD92-FFCE-4027-B7EF-954747655EA6Q37483026-63F1535B-09C6-43F2-B68F-7FD0DF6ED503Q37662286-3B9D1CB5-3F6E-4A32-8E05-AFD9A32F6096Q37796732-AABAD7BF-3A73-4E1B-BAF6-29E1726ADA81Q38219363-3A0B79D7-EB42-45C5-9A0A-911AAF7C550CQ38803056-44C23690-5984-40ED-A12B-8E55BF142236Q39051838-687D4801-3570-4368-98F6-1897F05C26EEQ39523561-68DF0A3F-D557-4782-8A79-ECF8161F7A3EQ40215805-EFABD0F4-7BDD-453D-96DE-77761916251DQ44724638-0991052E-29FD-4091-9210-1AEDD5D6E5D1Q44876224-25F3E4FF-C134-4176-B5AB-6D2B58EFF6ECQ46698294-10F815DB-89B8-413F-B673-19CA99D7526BQ47722850-7B54BD4D-E16D-4660-9441-9808DAAB1C90Q55049042-8C835E6D-4A80-411C-81F1-67ED62F21849
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Molecular aspects of multiple myeloma.
@ast
Molecular aspects of multiple myeloma.
@en
Molecular aspects of multiple myeloma.
@nl
type
label
Molecular aspects of multiple myeloma.
@ast
Molecular aspects of multiple myeloma.
@en
Molecular aspects of multiple myeloma.
@nl
prefLabel
Molecular aspects of multiple myeloma.
@ast
Molecular aspects of multiple myeloma.
@en
Molecular aspects of multiple myeloma.
@nl
P2093
P356
P1433
P1476
Molecular aspects of multiple myeloma
@en
P2093
N G Kastrinakis
P G Foukas
V G Gorgoulis
P304
P356
10.1023/A:1008331714186
P577
2000-10-01T00:00:00Z